MUC16 and neoplasm: According to the European Society of Gynecologic Oncologists (ESGO) and the European Society of Medical Oncology (ESMO), abandoning CA125 monitoring is not advised as it may signal the tumor recurrence in symptomless patients or may be helpful in clinical trials in patients who refuse frequent follow-up and those eligible for secondary cytoreduction at recurrence [259,260].